Wow. Don't know why the link gets garbled. Same thing goes for the search engine home page.
Google the 2018 AACR Annual meeting. Abstract titles are out.
Here they are.....
2709 / 1 - TTI-622 (SIRPa-IgG4 Fc), a CD47-blocking innate immune checkpoint inhibitor, suppresses tumor growth and demonstrates enhanced efficacy in combination with antitumor antibodies in both hematologic and solid tumor models
Gloria H. Y. Lin1, Natasja N. Viller1, Marilyse Chabonneau1, Laura Brinen1, Tapfuma Mutukura1, Karen Dodge1, Simone Helke1, Vien Chai1, Violetta House1, Vivian Lee1, Hui Chen1, Alison O'Connor1, Debbie Jin1, Rene Figueredo2, Saman Maleki Vareki2, Mark Wong1, Emma Linderoth1, Lisa D. S. Johnson1, Xinli Pang1, James Koropatnick2, Jeff Winston1, Penka S. Petrova1, Robert A. Uger1. 1Trillium Therapeutics Inc., Mississauga, ON, Canada; 2Lawson Health Research Institute, London, ON, Canada
2720 / 12 - The CD47-blocking innate immune checkpoint inhibitor, TTI-621, triggers CD47-mediated tumor cell apoptosis
Julia Bershadsky Izrailit, Natasja Nielsen Viller, Xinli Pang, Penka S. Petrova, Robert A. Uger, Jeff Winston, Emma Linderoth. Trillium Therapeutics Inc, Mississauga, ON, Canada |
